BioNTech SEFor BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook extends far beyond 2030. Yet despite all the strategic preparation, one key question will be answered in the coming months: can the clinical data live up to the high expectations surrounding BioNTech’s cancer strategy?
Tag Archive for: BioNTech
RocheRoche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate (ADC), underlining how the first collaboration has paid dividends for both sides.
Bayer AGPatent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against the makers of mRNA vaccines – just as the market has cooled and the pandemic feels firmly in the rear-view mirror. Understandable from a financial perspective, perhaps, but still raising questions about the timing.
BioNTechBioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
Ryvu Therapeutics zooKrakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
Medilink TherapeuticsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.